Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

References

• Nationmaster: China People Stats Available from: http://www.nationmaster.com/country-info/profiles/China/PeopleAccessed April 13, 2015
   Google Scholar
• hdrundporg/[homepage on the Internet]United Nations Human Development Reports: MediaUnited Nations Development Programme2015 [cited May 22, 2014]. Available from: http://hdr.undp.org/en/media/Lets-Talk-HD-HDI_2010.pdfAccessed April 26, 2015
   Google Scholar
• GuoYLiSTianZPanXZhangJWilliamsGThe burden of air pollution on years of life lost in Beijing, China, 2004–2008: retrospective regression analysis of daily deathsBMJ2013347f713924322399
   PubMed Web of Science ®Google Scholar
• ZhengWMcLerranDFRollandBABurden of total and cause-specific mortality related to tobacco smoking among adults aged $45 years in Asia: a pooled analysis of 21 cohortsPLoS Med2014114e100163124756146
   PubMed Web of Science ®Google Scholar
• ChenWZhengRZhangSReport of incidence and mortality in China cancer registries, 2009Chin J Cancer Res2013251102123372337
   PubMed Web of Science ®Google Scholar
• WangYCWeiLJLiuJTLiSXWangQSComparison of Cancer Incidence between China and the USACancer Biol Med20129212813223691468
   PubMedGoogle Scholar
• Canadian Cancer Society/National Cancer Institute of CanadaCanadian Cancer Statistics 2008Toronto, ONCanadian Cancer Society2008 Available from: https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2008-EN.pdfAccessed May 15, 2014
   Google Scholar
• CardosoFHarbeckNFallowfieldLKyriakidesSSenkusEESMO Guidelines Working GroupLocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii11vii1922997442
   PubMed Web of Science ®Google Scholar
• BishopJFDewarJTonerGCInitial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancerJ Clin Oncol19991782355236410561297
   PubMed Web of Science ®Google Scholar
• ChanSFriedrichsKNoelD303 Study GroupProspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerJ Clin Oncol19991782341235410561296
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNShawHDesaiNBharPPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• BradburyJDocetataxel downside highlightedLancet Oncology200567447
   Web of Science ®Google Scholar
• LeungPPTannockIFOzaAMPuodziunasADranitsarisGCost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancerJ Clin Oncol199917103082309010506603
   PubMed Web of Science ®Google Scholar
• LiNvan AgthovenMWillemsePUyl-de GrootCA cost – utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancerAnticancer Drugs200112653354011460000
   PubMed Web of Science ®Google Scholar
• GradisharWJKrasnojonDCheporovSPhase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survivalClin Breast Cancer201212531332122728026
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• DranitsarisGYuBWangLAbraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspectiveJ Oncol Pharm Pract Epub10142014
   Web of Science ®Google Scholar
• service2.bjpc.gov.cn [homepage on the Internet]Beijing Municipal Commission of Development and Reform [cited January 9, 2014]. Available from: http://service2.bjpc.gov.cn/bjpc/mediprice/MedicalService2.jsp)Accessed April 26, 2015
   Google Scholar
• HamiltonRAGordonTIncidence and cost of hospital admissions secondary to drug interactions involving theophyllineAnn Pharmacother19922612150715111482803
   PubMed Web of Science ®Google Scholar
• TorranceGWUtility approach to measuring health-related quality of lifeJ Chronic Dis19874065936033298297
   PubMedGoogle Scholar
• GafniAAlternatives to the QALY measure for economic evaluationsSupport Care Cancer1997521051119069609
   PubMed Web of Science ®Google Scholar
• ParidaensRBiganzoliLBruningPPaclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-overJ Clin Oncol200018472473310673513
   PubMed Web of Science ®Google Scholar
• WinerEPBerryDAWoolfSFailure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342J Clin Oncol200422112061206815169793
   PubMed Web of Science ®Google Scholar
• SledgeGWNeubergDBernardoPPhase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)J Clin Oncol200321458859212586793
   PubMed Web of Science ®Google Scholar
• JonesSEErbanJOvermoyerBRandomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancerJ Clin Oncol200523245542555116110015
   PubMed Web of Science ®Google Scholar
• BonneterreJRochéHMonnierADocetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failureBr J Cancer200287111210121512439707
   PubMed Web of Science ®Google Scholar
• Di LeoAGomezHLAzizZPhase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerJ Clin Oncol200826345544555218955454
   PubMed Web of Science ®Google Scholar
• AlbainKSNagSMCalderillo-RuizGGemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatmentJ Clin Oncol200826243950395718711184
   PubMed Web of Science ®Google Scholar
• DranitsarisGCottrellWSpirovskiBHopkinsSEconomic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancerJ Oncol Pharm Pract2009152677819036903
   PubMedGoogle Scholar
• MonteroAJAvanchaKGlückSLopesGA cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancerBreast Cancer Res Treat2012132274775122200867
   PubMed Web of Science ®Google Scholar
• MehtaDAHayJWCost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancerGynecol Oncol2014132367768324463160
   PubMed Web of Science ®Google Scholar
• research.tufts-nemc.org [homepage on the Internet]CEA registry: Who is CEVR?Tufts Medical Center2013 [cited May 28, 2014]. Available from: https://research.tufts-nemc.org/cear4/AboutUs/WhoisCEVR.aspxAccessed April 26, 2015
   Google Scholar